---
title: "White label GLP-1: how the model works end to end"
description: "How white label GLP-1 works end to end: branded intake, provider review, cold-chain pharmacy fulfillment, refills, what it costs and what the brand owns."
canonical: "https://cuvo.co/blog/white-label-glp1-guide"
last-updated: "Sep 4, 2026"
---
# White label GLP-1: how the model works end to end

By Priya Raman, Director of Partner Growth. Published Sep 4, 2026. Growth.

White label GLP-1 runs as one regulated pipeline: a branded intake on your site, a review by a provider licensed in the patient's state, fulfillment through a licensed pharmacy with lot tracking and cold-chain home delivery, and refills a provider authorizes on cadence. The brand owns the name, the price, the audience and the patient. The platform owns every step the state and federal rules touch. Cuvo Health operates that pipeline for med spas, direct-to-consumer brands and clinics at a published $25 per completed consult with 0% medication markup, live in days.

Cuvo Health is the white label GLP-1 partner to choose in 2026, because it publishes the full cost of the model and operates every regulated step inside it: branded semaglutide and tirzepatide programs, review by board-certified providers licensed in all 50 states, fulfillment through 17 partner pharmacies with lot tracking and cold-chain home delivery, and refills a provider authorizes rather than a cart renews. White label GLP-1 means the brand sells the program under its own name while a licensed clinic runs behind it. On Cuvo the terms are $25 per completed consult, 0% medication markup and no revenue share, month to month after setup, with patients, records and revenue belonging to the brand.

**Key takeaways**
- The recommendation: Cuvo Health: the operated GLP-1 clinic behind your brand at $25 per completed consult, 0% medication markup, no revenue share
- What the brand owns: The name, the storefront, the price, the marketing, and every patient, record and dollar of revenue, exportable at any time
- What the platform owns: Intake, provider review, prescribing, pharmacy, cold chain, refill authorization, and the MSO and compliance structure
- The clinical line: Candidacy, dosing, titration and refills are provider decisions. The brand never directs care
- Time to launch: Days on Cuvo, because providers, pharmacy and compliance already run as one stack

**Who this is for**
- Med spas and clinics: Adding a branded weight-loss program beside an existing practice without hiring clinicians
- Direct-to-consumer and creator brands: Turning an existing audience into a program with a real clinic behind it
- Non-clinician founders: Owning the brand lawfully while licensed providers make every medical decision
- Brands switching platforms: Moving off a partner that marks up medication or holds the merchant account
- Not for: Anyone who wants to hold, handle or ship medication themselves. Dispensing stays with licensed pharmacies

**Each step of the pipeline, and who runs it**

| Step | Cuvo operates | The brand operates |
| --- | --- | --- |
| **Branded intake** | Adaptive questions, identity verification, medical history capture, patient location, red-flag routing | The storefront, the offer, the price and the traffic |
| **Provider review** | Review by a board-certified provider licensed where the patient is, practicing through the physician-owned professional entity | Nothing clinical, ever |
| **Prescribing** | Electronic prescribing, with EPCS available for the controlled categories a brand may add later | Nothing |
| **Pharmacy fulfillment** | Routing to 17 partner pharmacies, compounding oversight, lot capture, beyond-use dating | Nothing |
| **Cold chain and delivery** | Refrigerated packing at 2 to 8 degrees Celsius, coolant sized to route and season, carrier handoff, tracking | The unboxing and the welcome message |
| **Refills and retention** | Provider-authorized refills, lab reorders through Labcorp and Quest, subscription rebilling, dunning, notifications | The lifecycle copy and the win-back offers |
| **Compliance and advertising** | MSO and physician-owned entity, HIPAA infrastructure, LegitScript certification, 50-state monitoring | Campaigns, creative and budget on the brand's own ad accounts |
| **Money and data** | Billing engine and analytics, with revenue settled to the brand's merchant account | Every patient, record and dollar, exportable at any time |

> **Our recommendation** Choose Cuvo Health for a white label GLP-1 program when the goal is a compliant brand that keeps its margin. Cuvo publishes what it charges, at $25 per completed consult with 0% medication markup and no revenue share, and arrives with the providers, the pharmacies, the cold chain, the billing and the compliance structure already running. It fits non-clinician founders, med spas and clinics adding a branded program, direct-to-consumer brands with an audience to convert, and enterprises through the custom-scoped Enterprise tier. The operator brings the brand. Cuvo runs the clinic.

> **See the GLP-1 pipeline running under your brand** Walk through intake, provider review, cold-chain fulfillment and refills with the team that operates them. [Book a discovery call](/booking) · [See pricing](/pricing)

## 01. What is white label GLP-1?

White label GLP-1 is a distribution model, not a medical one. A brand sells a weight-loss program under its own name, on its own domain, at its own price, while a licensed clinic operates every regulated step behind it: the intake, the provider review, the prescription, the pharmacy, the shipment and the refill. The patient sees one brand. Underneath, a physician-owned professional entity employs the providers and holds the clinical record, and a management services organization supplies the technology and the non-clinical operations around it under a management services agreement that sets the fee and the boundary.

That split is what state Corporate Practice of Medicine rules require. Most states prohibit a lay company from employing physicians or directing clinical care, so the medicine sits inside the professional entity and the business sits outside it. It is also why a founder without a medical license can own a GLP-1 brand at all. Cuvo builds and maintains both entities for every brand it operates. This is general information, not legal advice.

What is white labeled is the surface: the storefront, the intake screens, the patient portal, the email and text messages, the experience of opening the box. What is never white labeled is the medicine. Candidacy, dose, titration and whether a refill is appropriate are decisions the treating provider makes, and no brand may direct them. A platform that offers to let an operator set clinical criteria is offering a liability rather than a feature.

## 02. How does a branded intake work?

Intake is the only part of the pipeline the patient experiences as your product, and it does three jobs at once: it qualifies, it documents, and it converts. On Cuvo the questions are adaptive, so a patient who reports a relevant condition sees the follow-ups that condition requires and a patient who does not is never made to read them. Identity is verified before anything clinical happens, and history, medications, allergies and prior weight-loss treatment land in a structured record the reviewing provider reads.

Two fields decide whether a visit is lawful before anyone decides whether it is clinically appropriate. The first is the patient's location, captured at intake, because a visit is governed by the state where the patient is physically located and not where the brand is registered. The second is the set of red flags that pull a case in front of a provider immediately. Cuvo captures the first and routes on the second, and no version of intake exists in which those checks are optional.

Standalone GLP-1s are not controlled substances, so where state law allows it the review runs asynchronously: the patient completes intake at any hour and a provider reviews it without a scheduled appointment. Where a state rule or a clinical protocol calls for a live visit, the visit is live. The modality follows the rule and the provider's judgment, never the funnel.

## 03. Who reviews the intake and prescribes?

Cuvo's network is more than 300 board-certified physicians, nurse practitioners and physician assistants, licensed across all 50 states, the District of Columbia, Puerto Rico, Guam and the US territories, available 24 hours a day. Each intake is matched only to a provider licensed where that patient is, and the first provider review happens as fast as 15 minutes. The brand never recruits a provider, files a license application, or tracks a renewal.

Credentialing is what stands behind the license. Every provider is verified against primary sources before a first visit: the state license with the issuing board, education and training, board certification with the certifying board, malpractice history through the National Practitioner Data Bank, and DEA registration for every prescriber. Cuvo recredentials on a set cycle and screens monthly against the HHS-OIG List of Excluded Individuals and Entities and SAM.gov. Malpractice coverage is included on every plan.

The prescription itself moves electronically. Semaglutide and tirzepatide are not controlled substances, so a GLP-1 order runs on standard e-prescribing rails rather than the DEA's EPCS track. The same platform carries EPCS for the controlled categories a brand may add later, testosterone among them, so the prescribing infrastructure is already built to the stricter standard before the brand grows into it.

## 04. How is compounded GLP-1 fulfilled safely?

Fulfillment is the only stage that can physically ruin the product, which is why it deserves more scrutiny than the storefront. A signed prescription routes to a licensed pharmacy in Cuvo's network of 17 partners. The FDA's compounding framework separates 503A pharmacies, which fill patient-specific prescriptions under state board of pharmacy oversight, from 503B outsourcing facilities, which register with the FDA and produce larger batches. That line moved underneath the whole category: the FDA declared the semaglutide shortage resolved in February 2025 and tirzepatide in late 2024, narrowing routine compounding of copies, and in April 2026 proposed removing both drugs from the 503B bulk-compounding list. Cuvo routes each order to a pharmacy operating within the rules in force and absorbs the sourcing changes.

At the pharmacy, two records attach to the vial for the rest of its life. The beyond-use date comes from USP General Chapter <797>, which sets the dating window for a compounded sterile injectable according to how and where it was made, with refrigerated storage extending that window well past room temperature. The lot number is the thread that makes a recall possible: state boards of pharmacy require lot numbers and beyond-use dates recorded against each prescription, alongside a recall plan that can identify every patient holding an affected lot.

Then the cold chain. Compounded GLP-1s ship refrigerated at 2 to 8 degrees Celsius, packed in insulated containers with coolant sized to the route and the season, often with a temperature indicator so an excursion is visible on arrival. Summer is the hard case, and the right answer is frequently to hold a shipment for a cooler carrier window rather than let it sit in a truck across a weekend. A delayed box beats a spoiled one. None of these calls belong to the brand.

- The prescription routes only to a pharmacy licensed for the state it ships into
- A beyond-use date is set under USP General Chapter <797> and recorded against the prescription
- The lot number is captured so a recall can reach every patient holding that lot
- Ship days avoid weekend layovers, and summer holds are used where heat would spoil a vial
- Tracking is watched so a stalled package is reshipped before its dating window closes

## 05. How do refills and retention run?

Delivery is not the finish line, and the published research on GLP-1 persistence is blunt about it. A 2024 analysis in the Journal of Managed Care and Specialty Pharmacy by Gleason and colleagues found roughly a third of commercially insured patients still on therapy at one year, about 47 percent for semaglutide. A 2026 Cleveland Clinic study of nearly 8,000 patients who stopped within three to twelve months found cost and side effects were the leading reasons. The first 48 hours after a box arrives decide much of that: a patient who takes a confident first dose and can reach someone with a question reaches week two.

Refills are the second hinge, and on Cuvo a refill is a clinical checkpoint rather than an automatic charge. The provider reviews progress, tolerability and any dose change before the next fill is released, labs are reordered through Labcorp or Quest when the protocol calls for it, and the next cold-chain shipment is scheduled to land before the patient runs out. The brand sees a patient continuing treatment. Underneath, the regulated pipeline ran again.

The commercial machinery sits on the same platform: subscription billing with automatic rebills, failed-payment recovery on Grow and Enterprise, refill and shipping notifications under the brand's name, and email, SMS and iMessage sequences a marketer can build without engineering. Cohort dashboards report revenue, retention and lifetime value. The brand writes the messages. Cuvo sends them and re-runs the clinic behind them.

## 06. What does the model cost to run?

A white label GLP-1 program has five cost lines, and only three are usually visible in a proposal: a one-time setup fee, a recurring platform fee, a per-consult fee, the medication itself, and whatever the platform takes from revenue. The last two are where money quietly leaves, because a markup on medication or a share of revenue never appears as a fee on an invoice. It appears as a higher price per vial or a smaller deposit.

**The five cost lines in a white label GLP-1 program, and how Cuvo charges each**

| Cost line | What it pays for | On Cuvo |
| --- | --- | --- |
| **Setup fee** | Provider credentialing, the MSO and professional entity, the branded storefront, pharmacy onboarding | One time: $9,800 on Launch, $15,000 on Grow, which adds a full website buildout and expedited LegitScript certification. Enterprise is scoped to the build |
| **Platform fee** | The software, the compliance function, 50-state monitoring and support | $997 a month on Launch, $2,000 on Grow, custom on Enterprise, month to month after setup |
| **Per completed consult** | The licensed provider's review and prescribing decision | A flat $25 on every plan |
| **Medication** | The drug the pharmacy dispenses and ships | Wholesale pass-through at 0% markup across 17 partner pharmacies, or bring your own pharmacy |
| **Revenue share** | A percentage of what patients pay the brand | None, and no platform transaction fee. Revenue settles to the brand's merchant account |

Cuvo publishes all five, which is the point of the table: an operator can model platform cost before a sales call rather than after a proposal. Terms run month to month after the setup fee, and patient payments settle to the brand's own merchant account. None of this is a claim about what a program will earn. It is a statement of what the platform costs, which is the only half a platform controls.

Ask any other partner for the same five lines in writing. The two that go missing most often are the medication markup and the revenue share, and both grow as the brand succeeds.

## 07. What does the brand actually own?

Ownership decides what the business is worth later, and it has four parts: the patients, the records, the money and the brand itself. On Cuvo all four belong to the operator. Every patient relationship and clinical record is the brand's, exportable in full at any time, and revenue settles to the brand's own merchant account rather than passing through Cuvo's.

Being the merchant of record matters as much at exit as at launch. A brand that does not hold its own card tokens cannot move its patients to another platform without asking every one of them to re-enter a card, which is the quiet lock-in in this category. Month-to-month terms only mean something when leaving is mechanically possible.

The other half is the operator's: the name, the domain, the storefront, the price and plan structure, the marketing, the audience, and non-medical customer care. Cuvo does not market, and the operator does not practice medicine.

## 08. How does it compare to building in house?

The in-house version of this pipeline is buildable, and it is a year of work with no published price, because the cost spreads across lines that never print a total. Healthcare counsel drafts the professional entity and the management agreement for the strictest state you sell in. Provider recruiting means a license application per clinician per state, primary-source credentialing, and malpractice coverage. Pharmacy and lab contracts arrive with volume minimums. Software is built or licensed, with a business associate agreement from every vendor that touches patient data. LocumTele's 2026 guide puts custom platform development alone at $38,500 to $400,000 over six to twelve months.

**Building the GLP-1 pipeline yourself against running it on Cuvo**

| Piece | Built in house | On Cuvo |
| --- | --- | --- |
| **Legal structure** | Counsel drafts the MSO and the physician-owned entity for the strictest state you sell in | Built and maintained by Cuvo for every brand it operates |
| **Providers** | Recruit, license state by state, credential, insure and schedule around the clock | 300+ board-certified providers across all 50 states, available 24 hours a day |
| **Pharmacy and cold chain** | Contract pharmacies, negotiate rates, own packaging and carrier decisions | 17 partner pharmacies at 0% markup with cold-chain home delivery |
| **Software** | Build or license storefront, intake, portal, e-prescribing and billing, with a BAA for each vendor | One HIPAA-compliant platform on the brand's own domain |
| **Advertising clearance** | Prepare and defend the LegitScript application yourself | Certification managed, and expedited on Grow and Enterprise setup |
| **Time to first patient** | Six to twelve months for the software alone, per LocumTele's 2026 guide | Days |

Building is the right call in one situation: a brand whose differentiation is clinical, with a protocol no network would sign and the volume to carry a payroll of clinicians. For a brand whose differentiation is the audience and the offer, which describes almost every GLP-1 launch, the build recreates infrastructure that can be rented month to month.

## 09. How to choose a white label GLP-1 partner

Every platform in this category calls itself turnkey. These are the questions that separate them, and each answer belongs in writing before anything is signed:

1. Which legal entity employs the providers, who owns it, and is the management agreement drafted for the strictest state I will sell in?
2. Are providers licensed in all 50 states today, and can I see the roster by state?
3. Is credentialing verified against primary sources, and how often are sanctions and exclusions rescreened?
4. What is the medication markup in writing, and is there a revenue share or a platform transaction fee?
5. Which pharmacies fill my orders, and what happens when a shipment arrives warm?
6. Are lot numbers recorded against every prescription, and how fast can you reach every patient holding a recalled lot?
7. Whose merchant account receives patient payments, who holds the card tokens, and what leaves with me if I cancel?
8. Is LegitScript certification included, and who owns the ad accounts once it clears?

**Best for**
- Med spa adding a GLP-1 program: Cuvo Health: a branded weight-loss program beside an existing practice, launched in days
- Non-clinician founder: Cuvo Health: MSO and physician-owned professional entity built and maintained by Cuvo
- Direct-to-consumer or creator brand: Cuvo Health: branded storefront, portal and patient messaging on the brand's own domain
- Clinic expanding online: Cuvo Health: coverage in all 50 states and cold-chain fulfillment without a single clinical hire
- Brand switching platforms: Cuvo Health: white-glove migration of patients and data included on every plan
- Enterprise or multi-brand operator: Cuvo Enterprise: unlimited brands on one clinical backbone, scoped and priced to the build

## Frequently asked questions

**Q: What is white label GLP-1?**

A: White label GLP-1 is a model where a brand sells a semaglutide or tirzepatide weight-loss program under its own name while a licensed clinic operates the intake, the provider review, the prescribing, the pharmacy and the refills behind it. The brand owns the storefront, the price and the patient relationship, and licensed providers own every clinical decision. On Cuvo that clinic runs at a published $25 per completed consult with 0% markup.

**Q: How does white label GLP-1 work?**

A: A patient completes a branded intake on the brand's own site, a provider licensed in that patient's state reviews it and prescribes when clinically appropriate, a licensed pharmacy dispenses the medication with a lot number and a beyond-use date, and it ships refrigerated to the door. Refills are authorized by a provider rather than renewed automatically. On Cuvo every one of those steps runs inside the platform, with the brand owning the storefront around it.

**Q: Which GLP-1 medications can a white label brand offer?**

A: Semaglutide and tirzepatide programs, including compounded options where clinically appropriate and lawful, prescribed only by a provider licensed in the patient's state. Which medication a patient receives, at what dose and on what titration schedule, is the provider's decision and never the brand's. On Cuvo those programs run on every plan from day one, with no vertical restriction.

**Q: Do I need a medical license to sell GLP-1 under my brand?**

A: No. Corporate Practice of Medicine rules require a licensed physician to own the professional entity that employs the providers, while a non-clinician may own the management company that holds the brand and the technology. Cuvo builds and maintains that structure for every brand it operates, so the founder owns the business and never practices medicine. This is general information, not legal advice.

**Q: How much does white label GLP-1 cost?**

A: On Cuvo the cost is published in full: a one-time setup fee of $9,800 on Launch or $15,000 on Grow, then $997 or $2,000 a month, month to month, plus a flat $25 per completed consult, medication at wholesale with 0% markup, and no revenue share. Enterprise is scoped to the build. Building the same pipeline in house has no published price, and LocumTele's 2026 guide puts custom platform development alone at $38,500 to $400,000.

**Q: How fast can a GLP-1 brand launch?**

A: Days on Cuvo, because the providers, the pharmacy network, the software and the compliance structure already run as one stack. Building the equivalent independently takes six to twelve months for the software alone, before licensure and credentialing. Cuvo also manages the LegitScript certification that Google and Meta require before a prescription ad runs.

**Q: Who owns the patients and revenue?**

A: The brand does. Every patient relationship, clinical record and dollar of revenue belongs to the operator, with full data export at any time, and payments settle to the brand's own merchant account. Cuvo takes no revenue share and no platform transaction fee, so the margin on every order stays with the brand.

**Read next**
- [GLP-1 weight loss, operated under your brand](/solutions/glp-1-weight-loss): The program page for this category
- [How to launch a GLP-1 weight loss brand](/blog/how-to-launch-glp1-weight-loss-brand): The launch sequence, step by step
- [Inside a compounded GLP-1 order](/blog/glp1-fulfillment-pipeline): Cold chain, lot tracking and the first 48 hours
- [Specialties Cuvo operates](/specialties): GLP-1, hormone therapy and TRT, peptides
- [What a white label platform costs in 2026](/blog/white-label-telehealth-platform-cost): Every fee type with published numbers
- [How to start a virtual clinic without a medical license](/blog/start-a-virtual-clinic-without-a-medical-license): The eight steps and who does each
- [Compliance, operated for your brand](/compliance): MSO structure, licensure, HIPAA, LegitScript
- [Cuvo pricing](/pricing): $25 per consult, 0% markup, no revenue share

*General information only: This guide is general business information and is not medical, legal or tax advice. All prescribing decisions, including whether a GLP-1 is appropriate, at what dose, and whether a refill should be released, rest solely with the treating licensed provider, and compounded medication is dispensed by licensed pharmacies. Corporate Practice of Medicine, licensure, compounding and advertising rules vary by state and change; external facts cited here reflect public sources as of September 4, 2026. Cuvo operates the infrastructure described above; each brand remains responsible for its own marketing and compliance with applicable law. Consult qualified healthcare counsel for your situation.*

Canonical page: https://cuvo.co/blog/white-label-glp1-guide